UCB is building a new U.S. biologics manufacturing facility in Gwinnett County, Georgia. The state-of-the art campus will leverage AI, robotics, and automation. The project is part of UCB’s previously announced U.S. expansion and long-term commitment growth in the U.S. market.

The 460,000 sq.-ft. campus will sit on 79 acres and is designed to be a cornerstone of UCB’s global biologics manufacturing network. Once operational, the facility is expected to produce complex biologics 24/7 primarily for the U.S. market. In combination with UCB’s global network, the facility will strengthen UCB’s supply chain resilience globally while the new campus will serve as a hub for our U.S. manufacturing operations. 

The investment is expected to generate approximately $5 billion in total economic impact, including around 330 permanent highly skilled jobs.

UCB has received 15 FDA approvals or indication expansions, nine of which were secured in the past three years.

“This decision reflects our confidence in UCB’s long-term growth and our deep-rooted commitment to the U.S.,” said Jean-Christophe Tellier, UCB CEO. “By investing in Gwinnett County and the Rowen Foundation in Georgia, where our U.S. headquarters have been based for more than three decades, we are strengthening our biologics manufacturing capabilities, supporting our innovation pipeline, and creating high-quality jobs in a state that offers outstanding talent, a strong manufacturing tradition, and an ecosystem designed for sustainable, long-term success. This project is expected to generate approximately $5 billion in total economic impact, reflecting the broader value it will create for the region and its communities.”